Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicine

Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicine - Infliximab in sarcoidosis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39486

Enrollment

Registered

2010-10-08

Start date

2011-01-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Besnier Boeck Disease Interstitiel Lungdisease Sarcoidosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patients diagnosed with sarcoidosis. - patients treated with infliximab - capability of giving informed consent

Exclusion criteria

Exclusion criteria: · vaccination with live viral or bacterial vaccines within the previous 3 months, or within the next 3 months of the last doses. · cases of active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA) · serious infections within the past 2 months · serious right-sided heart failure or cor polmunale · known malignancy · Hepatitis B · paitients with allergic reactions to the monocolonal antibodies or their fragments · oppotunistic infections last 6 months · HIV · transplantation · pregnancy or bearstfeeding

Design outcomes

Primary

Measure	Time frame
Infliximab trough serum concentrations and the number of patients with at least one subtherapeutic concentration, being	—

Secondary

Measure	Time frame
Expression of TNF-a, TACE, and TNF-a receptors at mRNA and protein levels at basline, 3 and 6 months.	—

Countries

Netherlands

Outcome results